AAAAAA

   
Results: 1-11 |
Results: 11
ANTITUMOR-ACTIVITY OF TP3(ANTI-P80)-POKEWEED ANTIVIRAL PROTEIN IMMUNOTOXIN IN HAMSTER-CHEEK POUCH AND SEVERE COMBINED IMMUNODEFICIENT MOUSEXENOGRAFT MODELS OF HUMAN OSTEOSARCOMA
Authors: EK O WAURZYNIAK B MYERS DE UCKUN FM
Citation: O. Ek et al., ANTITUMOR-ACTIVITY OF TP3(ANTI-P80)-POKEWEED ANTIVIRAL PROTEIN IMMUNOTOXIN IN HAMSTER-CHEEK POUCH AND SEVERE COMBINED IMMUNODEFICIENT MOUSEXENOGRAFT MODELS OF HUMAN OSTEOSARCOMA, Clinical cancer research, 4(7), 1998, pp. 1641-1647
IN-VIVO TOXICITY, PHARMACOKINETICS, AND ANTICANCER ACTIVITY OF GENISTEIN LINKED TO RECOMBINANT HUMAN EPIDERMAL GROWTH-FACTOR
Authors: UCKUN FM NARLA RK ZEREN T YANISHEVSKI Y MYERS DE WAURZYNIAK B EK O SCHNEIDER E MESSINGER Y CHELSTROM LM GUNTHER R EVANS W
Citation: Fm. Uckun et al., IN-VIVO TOXICITY, PHARMACOKINETICS, AND ANTICANCER ACTIVITY OF GENISTEIN LINKED TO RECOMBINANT HUMAN EPIDERMAL GROWTH-FACTOR, Clinical cancer research, 4(5), 1998, pp. 1125-1134
IN-VIVO TOXICITY, PHARMACOKINETICS, AND ANTICANCER ACTIVITY OF GENISTEIN LINKED TO RECOMBINANT HUMAN EPIDERMAL GROWTH-FACTOR
Authors: UCKUN FM NARLA RK ZEREN T YANISHEVSKI Y MYERS DE WAURZYNIAK B EK O SCHNEIDER E MESSINGER Y CHELSTROM LM GUNTHER R EVANS W
Citation: Fm. Uckun et al., IN-VIVO TOXICITY, PHARMACOKINETICS, AND ANTICANCER ACTIVITY OF GENISTEIN LINKED TO RECOMBINANT HUMAN EPIDERMAL GROWTH-FACTOR, Clinical cancer research, 4(5), 1998, pp. 1125-1134
IN-VIVO TOXICITY AND PHARMACOKINETIC FEATURES OF B43 (ANTI-CD19)-GENISTEIN IMMUNOCONJUGATE IN NONHUMAN-PRIMATES
Authors: MESSINGER Y YANISHEVSKI Y EK O ZEREN T WAURZYNIAK B GUNTHER R CHELSTROM L CHANDANLANGLIE M SCHNEIDER E MYERS DE EVANS W UCKUN FM
Citation: Y. Messinger et al., IN-VIVO TOXICITY AND PHARMACOKINETIC FEATURES OF B43 (ANTI-CD19)-GENISTEIN IMMUNOCONJUGATE IN NONHUMAN-PRIMATES, Clinical cancer research, 4(1), 1998, pp. 165-170
IN-VIVO TOXICITY AND PHARMACOKINETIC FEATURES OF B43 (ANTI-CD19)-GENISTEIN IMMUNOCONJUGATE IN NONHUMAN-PRIMATES
Authors: MESSINGER Y YANISHEVSKI Y EK O ZEREN T WAURZYNIAK B GUNTHER R CHELSTROM L CHANDANLANGLIE M SCHNEIDER E MYERS DE EVANS W UCKUN FM
Citation: Y. Messinger et al., IN-VIVO TOXICITY AND PHARMACOKINETIC FEATURES OF B43 (ANTI-CD19)-GENISTEIN IMMUNOCONJUGATE IN NONHUMAN-PRIMATES, Clinical cancer research, 4(1), 1998, pp. 165-170
IN-VIVO TOXICITY AND PHARMACOKINETIC FEATURES OF B43(ANTI-CD19)-GENISTEIN IMMUNOCONJUGATE
Authors: EK O YANISHEVSKI Y ZEREN T WAURZYNIAK B GUNTHER R CHELSTROM L CHANDANLANGLIE M SCHNEIDER E MYERS DE EVANS W UCKUN FM
Citation: O. Ek et al., IN-VIVO TOXICITY AND PHARMACOKINETIC FEATURES OF B43(ANTI-CD19)-GENISTEIN IMMUNOCONJUGATE, Leukemia & lymphoma, 30(3-4), 1998, pp. 389-394
IN-VIVO TOXICITY, PHARMACOKINETICS, AND ANTILEUKEMIC ACTIVITY OF TXU (ANTI-CD7)-POKEWEED ANTIVIRAL PROTEIN IMMUNOTOXIN
Authors: WAURZYNIAK B SCHNEIDER EA TUMER N YANISHEVSKI Y GUNTHER R CHELSTROM LM WENDORF H MYERS DE IRVIN JD MESSINGER Y EK O ZEREN T LANGLIE MC EVANS WE UCKUN FM
Citation: B. Waurzyniak et al., IN-VIVO TOXICITY, PHARMACOKINETICS, AND ANTILEUKEMIC ACTIVITY OF TXU (ANTI-CD7)-POKEWEED ANTIVIRAL PROTEIN IMMUNOTOXIN, Clinical cancer research, 3(6), 1997, pp. 881-890
PHARMACOKINETIC FEATURES, IMMUNOGENICITY, AND TOXICITY OF B43(ANTI-CD19)-POKEWEED ANTIVIRAL PROTEIN IMMUNOTOXIN IN CYNOMOLGUS MONKEYS
Authors: UCKUN FM YANISHEVSKI Y TUMER N WAURZYNIAK B MESSINGER Y CHELSTROM LM LISOWSKI EA EK O ZEREN T WENDORF H LANGLIE MC IRVIN JD MYERS DE FULLER GB EVANS W GUNTHER R
Citation: Fm. Uckun et al., PHARMACOKINETIC FEATURES, IMMUNOGENICITY, AND TOXICITY OF B43(ANTI-CD19)-POKEWEED ANTIVIRAL PROTEIN IMMUNOTOXIN IN CYNOMOLGUS MONKEYS, Clinical cancer research, 3(3), 1997, pp. 325-337
IN-VIVO BIOTHERAPY OF HL-60 MYELOID-LEUKEMIA WITH A GENETICALLY-ENGINEERED RECOMBINANT FUSION TOXIN DIRECTED AGAINST THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR
Authors: PERENTESIS JP GUNTHER R WAURZYNIAK B YANISHEVSKI Y MYERS DE EK O MESSINGER Y SHAO Y CHELSTROM LM SCHNEIDER E EVANS WE UCKUN FM
Citation: Jp. Perentesis et al., IN-VIVO BIOTHERAPY OF HL-60 MYELOID-LEUKEMIA WITH A GENETICALLY-ENGINEERED RECOMBINANT FUSION TOXIN DIRECTED AGAINST THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR, Clinical cancer research, 3(12), 1997, pp. 2217-2227
IN-VIVO TOXICITY, PHARMACOKINETIC FEATURES AND IMMUNOGENICITY OF B43 (ANTI-CD19)-GENISTEIN IMMUNOCONJUGATE IN MICE AND NONHUMAN-PRIMATES
Authors: MESSINGER Y YANISHEVSKI Y EK O ZEREN T WAURZYNIAK B GUNTHER R CHELSTROM L CHANDANLANGLIE M SCHNEIDER E MYERS DE UCKUN FM
Citation: Y. Messinger et al., IN-VIVO TOXICITY, PHARMACOKINETIC FEATURES AND IMMUNOGENICITY OF B43 (ANTI-CD19)-GENISTEIN IMMUNOCONJUGATE IN MICE AND NONHUMAN-PRIMATES, Blood, 90(10), 1997, pp. 1467-1467
IN-VIVO ANTIMYELOID LEUKEMIA ACTIVITY OF A RECOMBINANT FUSION TOXIN TARGETED TO THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR
Authors: PERENTESIS JP GUNTHER R WAURZYNIAK B CHELSTROM LM BENDEL AE DAVIES SM SHAO Y WARMAN B CHANDANLANGLIE M WADDICK KG YANISHEVSKI Y EVANS WE UCKUN FM
Citation: Jp. Perentesis et al., IN-VIVO ANTIMYELOID LEUKEMIA ACTIVITY OF A RECOMBINANT FUSION TOXIN TARGETED TO THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR, Blood, 88(10), 1996, pp. 831-831
Risultati: 1-11 |